A thesis-driven earliest stage firm looks to lead investments in early-stage companies that are pre-seed. The firm is currently investing out of their second fund of USD 67 million. The firm primarily participates in equity investments including SAFEs but will consider other types of capital structures as requested by a founder. The firm invests largely in companies based in the United States and Canada but will also consider Europe and Latin America.
The firm is primarily interested in investing in companies in the digital health, diagnostics, and medical technology sectors with a focus in platform technologies. The firm will not consider investments in medical device companies. However, the firm will consider therapeutics with a platform technology component. The firm will only invest in technologies that are still pre-clinical and in development. The firm is disease agnostic and will consider companies across all indications including orphan diseases.
The firm will work with experienced and inexperienced management teams. The firm looks to invest in founders who are dedicated to their technology and their company. The firm is an active investor and will take an observer board seat as determined on a case-by-case basis. The firm prefers to act as a lead investor.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Leave a Reply